natgillin/translations-raw huggingface dataset:
The hybridoma cell line according to claim 9 being the hybridoma deposited according to the Budapest Treaty at the Advanced Biotechnology Center, Genoa, Italy, under No. 
Hibridomna stanična linija u skladu s patentnim zahtjevom 9, naznačena time što pripada hibridomu deponiranom u skladu s Budimpeštanskim ugovorom u Centru za naprednu biotehnologijuza naprednu biotehnologiju u Genovi, Italija, pod br.
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 800,000, and 
najmanje jedan polietilen oksid koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; i
wherein PrG has the same meaning as in Formula (III). 
(v), gdje PrG ima isto značenje kao u formuli (III).
The geometry of the container 12 of FIG. 
Broj objave europskog patenta:
Assembly of a scent module (3) and an air scenting device(1), said air scenting device comprising: 
Sklop mirisnog modula (3) i aparata (1) za parfimiranje zraka, navedeni aparat za parfimiranje zraka koji sadrži:
Possible therapeutical applications for said antagonists are inflammatory, allergic and autoimmune disorders, such as asthma and chronic bronchitis (also induced by irritants), allergic, vasomotor and viral rhinitis, obstructive pulmonary disease (COPD), rheumatoid arthritis, chronic inflammatory diseases of the bowel (Crohn's disease and ulcerative colitis), glomerulonephritis, psoriasis, rash, acute and chronic cystitis; degenerative disorders characterized by fibrosis, such as hepatic cirrhosis, glomerulopathies and pulmonary fibrosis, arteriosclerosis; thanks to their analgesic activity, in the treatment of both acute and chronic pain, for example in burns, cephalea, insects bites, chronic pain in cancer patients; in disorders of the cardiovascular apparatus such as septic, allergic and post-traumatic shocks, and hepatic cirrhosis by hepatorenal syndrome; as anticancer and antiangiogenetics; in the treatment of hypotension and of alopecia. 
Moguće terapijske primjene rečenih antagonista su upalni, alergijski i autoimuni poremećaji, kao što je astma i kronični bronhitis (također induciran iritantima), alergijski, vazomotorni i virusni rinitis, kronična opstruktivna plućna bolest (COPD), reumatoidni artritis, kronične upalne bolesti crijeva (kronova bolest i ulcerativni kolitis), glomerulonefritis, psorijaza, osip, akutni i kronični cistitis; degenerativni poremećaji karakterizirani fibrozom kao što je hepatička ciroza, glomerulopatije i plućna fibroza, arteroskleroza, a zahvaljujući njihovoj analgetskoj aktivnosti u tretmanu akutne i kronične boli, primjerice opeklina, glavobolje, ugriza insekta, kronične boli kod pacijenata s karcinomom; kod poremećaja kardiovaskularnog aparata kao što je septički, alergijski i postraumatski šok i hepatička ciroza od hepatorenalnog sindroma; kao antikancerogena i antiangiogenetska sredstva, u tretmanu hipotenzije i alopecije. Detaljni opis
Measuring changes in the detectable signal produced by the probe of (ii) 
(ili) mjerenja promjena u detektabilnom signalu dobivenom iz sonde u koraku (ii).
A computer product comprising a computer readable medium storing a plurality of instructions that when executed control a computer system to estimate a fractional concentration of clinically-relevant DNA in a biological sample, the biological sample including the clinically-relevant DNA and other DNA, wherein the instructions are for performing the method of any one of claims 1 to 14. 
Metoda prema patentnom zahtjevu 14, koja se dodatno sastoji od testiranja uzorka na fetalnu aneuploidiju kada je prvi parametar iznad kalibracijske vrijednosti. Računalni program koji se sastoji od niza uputa koje računalni sustav može izvršiti, tako da kada se izvrše kontroliraju računalni sustav kako bi izvršio metodu prema bilo kojem od prethodnih zahtjeva.
The printing system of claim 5, further comprising a clock with a time counter configured to send timing signals to the controller. 
Sustav za pisanje u skladu s patentnim zahtjevom 3, naznačen time što dodatno sadrži sat s brojačem vremena (550), konfiguriranim za slanje vremenskih signala u regulator (510).
the first fragment has a first proximal end; 
(iii) prvi fragment ima prvi proksimalni kraj;
Also preferred in such a kit is the means for measuring the total content of bacteria in a sample from a subject comprising a general primer set specific for bacterial 16s rDNA. 
Komplet prema zahtjevu 10, naznačen time da sredstva za mjerenje ukupnog sadržaja bakterija u uzorku od subjekta sadrže općeniti skup početnica specifičan za bakterijsku 16s rDNA.
A method for converting an organic material into hydrocarbon fuels is disclosed. 
Metoda za pretvorbu organskog materijala u ugljikohidratna goriva, obuhvaća korake:
or a pharmaceutically acceptable salt thereof. Use of a cyclosporin according to claim 1 in the preparation of a pharmaceutical composition for inhibiting HCV replication. 
Uporaba ciklosporina u skladu sa zahtjevom 1, naznačena time, da se koristi za pripravu farmaceutskog pripravka za inhibiciju HCV replikacije.
wherein (R1)p is as defined for formula (I), with a compound of formula (III): wherein R3 and R4 are as defined for formula (I) and X is a leaving group, and thereafter optionally: 
HR P20100114 T1 NH (RIP gdje (R,), je definiran kao za formulu (1), sa spojem formule (III):
Certain embodiments relate to one or more capture complexes that comprise a capture entity, an antibody in a test sample, and a first detector, wherein the capture entity binds to the antibody and wherein the first detector comprises a Fc-binding molecule conjugated to a first detectable entity and binds to the Fc region of the antibody. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što prvi detektor sadrži molekulu koja se veže na Fc, konjugiranu s prvim detektibilnim entitetom, te što je molekula koja se veže na Fc protein A i/ili protein G.
is H, OR10, NR11R12 or Q1; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R7; or and R5 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and O, said ring optionally substituted with 1 to 4 substituents independently selected from the group consisting of C1-C2 alkyl, halogen, -CN, -NO2 and C1-C2 alkoxy; 
je H, OR10, NR11R12; ili Q1; ili C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C3-C6 cikloalkil, C4-C7 alkilcikloalkil ili C4-C7 cikloalkilalkil, od kojih je svaki opcionalno supstituiran s jednim ili više supstituenata koji su neovisno odabrani od R7; ili se R4 i R5 uzimaju zajedno s dušikom na kojega su priključeni, u svrhu tvorbe prstena koji sadrži od 2 do 6 atoma ugljika i opcionalno jedan dodatni atom odabran iz skupine koju čine N, S i O, gdje je navedeni prsten opcionalno supstituiran s jednim do četiri supstituenta koji su neovisno odabrani iz skupine koju čine: C1-C2 alkil, halogen, -CN, -NO2 i C1-C2 alkoksi;
The process or composition of claim 13, wherein the specific turbidity of the composition is between 0.3 cm2/g and 0.6 cm2/g. 
Sastav prema patentnom zahtjevu 12, naznačen time, da je specifična zamućenost sastava između 0,3 cm?/g i 0,6 cm'"/g.
In some embodiments the metabolic-related disorder is dyslipidemia. 
U nekim oblicima metabolički pripadajući poremećaj je dislipidemija.
The process of claim 1, wherein said second solvent is selected from the group consisting of alcohols, ethers, ketones, esters, xylene, and N-methylpyrrolidinone, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine alkohols, eteri, ketoni, esteri, ksilen i N-metilpirolidinon, te smjese 2 ili više njih.
Pharmaceutical form according to anyone of claims 1 to 3 wherein the compound presenting dependent or independent pH quaternary ammonium groups is a non water soluble compound. 
Farmaceutski oblik u skladu s jednih od patentnih zahtjeva 1 naznačen time što tvar koja predstavlja ovisne ili neovisne pH skupine kvaternog amonijaka nije tvar topiva u vodi.
For example, the renewable fuel oil may have a solids content of less than 4 wt. %, less than 3 wt. %, less than 2.5 wt. %, less than 2 wt. %, less than 1 wt. %, less than 0.5 wt. %, or less than 0.1 wt. %. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time što neobogaćeno obnovljivo ulje goriva ima sadržaj krutina od manje od 0,5 wt. % i/ili manje od 0,1 wt. %.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in a method of improving in a subject in need thereof a biochemical marker of a LSD over time, wherein the method comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1 kako bi se kod pacijenta kojemu je to potrebno poboljšao biokemijski marker LSD-a tijekom vremena, pri čemu uporaba sadrži primjenu terapeutski djelotvorne količine acetil-leucina na subjektu kojemu je to potrebno kroz razdoblje odabrano od barem oko 3 mjeseca, barem oko 6 mjeseci, barem oko 1 godine, barem oko 2 godine i barem oko 5 godina.
Node according to claim 12, characterized in that the first communication system (11) is a system according to the GSM-R standard while the second communication system (12) is a system according to the LTE standard. 
Čvor u skladu s patentnim zahtjevom 10, naznačen time što je prvi komunikacijski sustav (11) sustav prema standardu GSM-R, dok je drugi komunikacijski sustav (12) sustav prema standardu LTE.
HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, which is the rate determining step in the biosynthesis of cholesterol. 
HMG-CoA reduktaza katalizira pretvorbu HMG-CoA u mevalonat, što je odlučujući korak u biosintezi kolesterola.
The at least one swirl chamber by-pass port (502, 503, 504, 505) allow air to flow (shown by arrows labelled 5) from a proximal end of the airflow adaptor to a distal end of the airflow adaptor (501) independently of the swirl-chamber (514) when a breath-induced low pressure is applied to the distal end of the airflow adaptor. 
703) koja ima proksimalni kraj i distalni kraj, adaptor protoka zraka (100; 200; 300; 501; 601; 702) dalje obuhvaća barem jednu drugu cijev (102-105; 204-206; 304-306; 502-505; 603-606) za omogućavanje strujanja zraka od proksimalnog kraja adaptora (100; 200; 300; 501; 601; 702) do distalnog kraja adaptora (100; 200;
Ra is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; 
Ra je vodik, alkil ili supstituirani alkil, alkenil ili supstituirani alkenil, alkinil ili supstituirani alkinil, cikloalkil ili supstituirani cikloalkil, cikloalkenil ili supstituirani cikloalkenil, heterocikl ili supstituirani heterocikl, ili aril ili supstituirani aril;
Number of expressors 
Broj međunarodne objave:
Receptacle according to claim 1 wherein the tube contains a liquid medical preparation which contains iron. 
Spremnik u skladu s patentnim zahtjevom 1, naznačen time što savitljiva cijev sadržava tekući pripravak koji sadržava željezo.
A pharmaceutical composition comprising a lipid particle of claim 6 a pharmaceutically acceptable carrier. 
HR P20182156 T1 11 i farmaceutski prihvatljiv nosač.
The valve of claim 10, wherein the openings of the outflow ring of openings are larger than the openings of both the inflow ring of openings and the at least one intermediate ring of openings. 
Sklop prema patentnom zahtjevu 1, naznačen time da dijelovi strukture listića (14) štrče kroz otvore dok je protetski aortni ventil (10) u radijalno srušenom obliku.
The first step is the laying of the cable. 
(32) Datum podnošenja prve prijave: 22.09.2008.
When the latch keys release the resulting potential energy in the wireline converts to kinetic energy which accelerates the mass of the weight bars. 
Kada zasun oslobodi rezultirajuću potencijalnu energiju u žicanoj vezi dolazi do njene transformacije u kinetičku energiju koja ubrzava masu teških šipki.
The second intermediate layer 12 is made of hydrophobic polyester or polypropylene or of other equivalent hydrophobic fibers. 
(12) sastoji od hidrofobnih vlakana poliestera ili polipropilena ili drugih ekvivalentnih hidrofobnih vlakana.
The extended release dosage form of items 84 to 94, wherein the composition comprises at least about 80 % (by wt) of polyethylene oxide. 
Oblik doziranja s produljenim otpuštanjem prema zahtjevima od 1 do 11, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida.
said subject is an adult or young adult. 
(iv) spomenuti subjekt je odrasla osoba ili mlada osoba.
The solid oral extended release pharmaceutical dosage form of claim 1 or 2, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 *C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37? C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1,4 1 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
A compound that binds to and activates the erythropoietin receptor (EPO-R), which compound comprises a peptide dimer having the formula: 
Spoj koji se veže na i aktivira eritropoctinski receptor (EPO-R), gdje navedeni spoj sadrži peptidni dimer formule:
characterised in that: said acid(s) of step b) each having a pKa of greater than 2.5 and less than or equal to 7, when measured at 20°C, associated with the ionisation of their first available hydrogen, and a corresponding anion formed on loss of this first available hydrogen capable of forming water-soluble calcium salts; 
(i) svaka navedena kiselina ili navedene kiseline iz koraka b) imaju pKa veći od 2.5 1 manji od ili jednak 7, mjereno kod 20*C, povezano sa ionizacijom njihovog prvog dostupnog vodika, te odgovarajući anion formiran na mjestu ovog prvog dostupnog vodika koji je sposoban formirati kalcijeve soli topive u vodi;
The invention relates to a polypeptide comprising the amino acid sequence set out in SEQ ID NO: 2 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1, or a variant polypeptide or variant polynucleotide thereof, wherein the variant polypeptide has at least 96% sequence identity with the sequence set out in SEQ ID NO: 2 or the variant polynucleotide encodes a polypeptide that has at least 96% sequence identity with the sequence set out in SEQ ID NO: 2. 
Polipeptid koji obuhvaća sekvencu aminokiseline navedenu u SEQ ID NO:2 ili sekvencu aminokiseline koja je kodirana s nukleotidnom sekvencom SEQ ID NO:l1, ili njegovu varijantu polipeptida ili njegovu varijantu polinukleotida, naznačen time da varijanta polipeptida ima najmanje 98% identičnosti sekvence sa sekvencom prikazanom u SEQ ID NO:2 ili varijanta polinukleotida kodira polipeptid koji ima najmanje 98% identičnosti sekvence sa sekvencom prikazanom u SEQ ID NO:2, pri čemu polipeptid ima aktivnost beta-glukozidaze.
Erythropoietin solution formulation 
FORMULACIJA OTOPINE ERITROPOETINA
q represents 0 to 2; or a salt thereof. The dihydrospiro-[cycloalkylamine]-pyrimidone derivative according to claim 1, wherein R4 represents a hydrogen atom, a C1-4 alkoxy carbonyl group, a C1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group or a C1-4 alkoxy group. 
Dihidrospiro[cikloalkilamin|pirimidonski derivat, ili njegova sol, ili njen solvat ili hidrat, prema patentnom zahtjevu 1, naznačen time što R4 predstavlja atom vodika, C;4 alkoksikarbonilnu skupinu, C;.4 alkilnu skupinu, izborno supstituiranu s 1 do 4 supstituenta, koje se bira između atoma halogena, hidroksilne skupine ili C,.g alkoksi skupine.
the operation (drawing or storing) and data concerning the involved bags are logged in a “history” file (.log file or a DBS) which is stored locally on the apparatus 1 but it is readable by the hospital management system 17 through the communication module 19 . 
A5) postupak (vađenja ili pohranjivanja) i podaci koji se odnose na pojedinačne vrećice se zapisuju u datoteku "povijesti" (dnevnik rada ili DBS) koja se pohranjuje lokalno na uređaju 1, ali se može čitati pomoću sustava za vođenje bolnice 17 preko komunikacijskog modula 19.
The system of claim 5, characterized in that the protective cover, the convex lenses, the concave lens, the fiber-optic bundle, and the rear end lens group are all made of materials that are capable transmitting the full-spectrum rays of the sunlight; and materials of the reflectors and a reflective film covered on an inner surface of the light conduction cylinder have an absorption rate or a filtration rate of an ultraviolet light, a visible light, and an infrared light of ≤6%. 
Sustav prema zahtjevu 5, naznačen time što zaštitni poklopac, konveksne leće, konkavna leća, svjetlovodmi snop 1 leća na stražnjem kraju su svi napravljeni od materijala koji su sposobni prenositi zrake punog spektra sunčeve svjetlosti; i materijali reflektora 1 reflektirajući film prekriven na unutarnjoj površini cilindra za provođenje svjetla imaju stopu apsorpcije ili stopu filtracije ultraljubičaste svjetlosti, vidljive svjetlosti, te infracrvene svjetlosti od <6%. HR P20181860 T1
The slurry according to claim 1, wherein the mineral material is selected from calcium carbonate, clay, or any mixture thereof, more preferably from natural ground calcium carbonate. 
Mulj u skladu s patentnim zahtjevom 1, naznačen time što je mineralni materijal prirodni usitnjeni kalcijev karbonat.
contacting said GNCC of step a) with said acid of step b) and with said CO2 of step c); 
kontakt navedenog GNCC iz koraka a) sa navedenom kiselinom iz koraka b) i sa navedenim CO2 iz koraka c);
Half-molds 70 a, 70 b are closed (FIG. 3 b) to form a cavity 72 complementary in shape to casing 3 . 
Polutke kalupa 70a, 70b se zatvaraju (Slika 3b) da oblikuju šupljinu 72, oblikom komplementarnu kućištu 3.
The column was eluted with 8:2 heptane/IPAc and fractions collected. 
Stupac je bio eluiran s 8:2 heptanom/IPAc i frakcije su bile skupljene.
The method of claim 25, wherein R2 is —CH2N(R9)2 or —N(R9)2. The method of claim 26, wherein R9 is independently selected from the group consisting of H, Me, Et, n-propyl, isopropyl, and —CH2carbocyclyl. 
Spoj prema patentnom zahtjevu 1 ili zahtjevu 3, naznačen time što je R9 neovisno odabran iz skupine koju čine H, Me, Et, -CH2fenil i -CH2karbociklil.
To the resulting emulsion was added ethyl acetate (250 mL). 
Rezultirajući emulziji dodan je etilni acetat (250 mL).
n′)—Driving back the milling heads in direction Z; 
n ́) - povlačenje glava za glodanje (1g-1t) u smjeru Z;
This may result in a spontaneous transformation upon storage of the composite material. 
To može rezultirati u spontanoj transformaciji nakon skladištenja kompozitnog materijala.
providing at least one candidate sequence which consists of an amino acid sequence modified by substituting 1 or two amino acid residues to an original amino acid sequence, wherein the original amino acid sequence is selected from the group consisting of SEQ ID NO: 194, 174, 178, and 186; 
osiguravanja najmanje jednog slijeda kandidata koji ima aminokiselinski slijed modificiran zamjenom jednog ili dva aminokiselinska ostatka u izvornom aminokiselinskom slijedu, gdje se izvorni aminokiselinski slijed se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78;
The avian cell according to any one of claims 11 to 13, wherein it further comprises a nucleic acid sequence coding a substance of interest 
Ptičja stanica prema bilo kojem od patentnih zahtjeva 11 do 15, naznačena time da nadalje sadrži sekvneciju nukleinske kiseline koja kodira tvar od interesa.
The pharmaceutical composition of any one of claims 2 to 5, wherein the pharmaceutical composition has a pH of from 4 to 6. 
Farmaceutska kompozicija patentnog zahtjeva 3 ili patentnog zahtjeva 4, gdje farmaceutska kompozicija ima pH od oko 4 do oko 6.
is selected from the group consisting of hydroxy, halogen, C1-4alkyl, C1-4alkoxy, halogen substituted C1-4alkyl and halogen substituted C1-4alkoxy; 
se R10 neovisno odabire iz skupine koju sačinjavaju hidroksi, halogen, C1-4alkil, C1-4alkoksi, halogenom supstituiran C1-4alkil i halogenom supstituiran C1-4alkoksi;
The anti-LAG-3 antibody and/or the anti-PD-1 antibody for use according to any one of claims 1-15, wherein the solid tumor is chosen from melanoma, non-small cell lung cancer (NSCLC), human papilloma virus (HPV)-related tumor, and gastric adenocarcinoma. 
Anti-LAG-3 antitijelo i/ili anti-PD-1 antitijelo za primjenu u skladu sa bilo kojim od patentnih zahtjeva 1-14, gdje solidni tumor je izabran od melanoma, ne-sitnostaničnog raka pluća (non-small cell lung cancer - NSCLC), tumora povezanog sa humanim papiloma virusom (HPV), i želučani adenokarcinom.
or a pharmaceutically acceptable salt or a stereoisomer thereof. 
ili njihova farmaceutski prihvatljiva sol ili njihov stereoizomer.
Preferably, this is carried out at an increased temperature, in particular at a temperature which, dependent on the species of wood, varies between 70 °C and 100 °C. 
Poželjno je da se to izvodi kod povišene temperature, naročito kod temperature koja, ovisno o vrsti drva, varira između 70%C i 100%C.
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same 
(54) Naziv izuma: = ANTITIJELA LAKOG LANCA PROIZVEDENA HISTIDINOM I GENETSKI MODIFICIRANI
Packaging unit according to one or more of the foregoing claims, wherein the label comprises an embossing shape such that the embossed label behaves as a stacking element. 
Jedinica za pakiranje prema jednom ili više od prethodnih zahtjeva, naznačena time da naljepnica sadrži utisnuti oblik tako da se utisnuta naljepnica ponaša kao element za slaganje na hrpu.
In a second aspect, the present invention provides polypeptide comprising an amino acid sequence at least 75% identical to an amino acid sequence according to SEQ ID NO:1, wherein the polypeptide degrades a PQPQLP (SEQ ID NO:34) peptide at pH 4; 
Polipeptid koji sadrži aminokiselinsku sekvencu najmanje 75% identičnu aminokiselinskoj sekvenci u skladu sa SEK ID BR:1, gdje (a) polipeptid degradira POPQLP (SEK ID BR:34) peptid na pH 4;
loading the composition onto a chromatography material in an amount in excess of the dynamic binding capacity of the chromatography material for the polypeptide, eluting the polypeptide from the chromatography material under conditions wherein the one or more contaminants remain bound to the chromatography material, and 
punjenje sastava materijalom za mješoviti način rada, ionsku izmjenu, hidrofobnu interakciju ili materijalom afinitetne kromatografije u količini suvišnoj za kapacitet dinamičkog vezivanja kromatografskog materijala za protutijelo uporabom pufera za punjenje, pri čemu je koeficijent raspodjele kromatografskog materijala za protutijelo veći od 30,